99mTc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice

99mTc-cAbVCAM1-5, a single-domain antibody fragment directed against mouse or human vascular cell adhesion molecule 1 (VCAM-1), recently has been proposed as a new imaging agent for the detection of inflamed atherosclerotic lesions. Indeed, in a mouse model of atherosclerosis, 99mTc-cAbVCAM1-5 specifically bound to VCAM-1–positive lesions, thereby allowing their identification on SPECT images. The purpose of the present study was to investigate 99mTc-cAbVCAM1-5 imaging sensitivity using a reference statin therapy. Methods: Thirty apolipoprotein E–deficient mice were fed a western-type diet. First, the relationship between the level of VCAM-1 expression and 99mTc-cAbVCAM1-5 uptake was evaluated in 18 mice using immunohistochemistry and autoradiography. Second, longitudinal SPECT/CT imaging was performed on control (n = 9) or atorvastatin-treated mice (0.01% w/w, n = 9). Results: 99mTc-cAbVCAM1-5 uptake in atherosclerotic lesions correlated with the level of VCAM-1 expression (P < 0.05). Atorvastatin exerted significant antiatherogenic effects, and 99mTc-cAbVCAM1-5 lesion uptake was significantly reduced in 35-wk-old atorvastatin-treated mice, as indicated by ex vivo γ-well counting and autoradiography (P < 0.05). SPECT imaging quantification based on contrast-enhanced CT was reproducible (interexperimenter intraclass correlation coefficient, 0.97; intraexperimenter intraclass correlation coefficient, 0.90), and yielded results that were highly correlated with tracer biodistribution (r = 0.83; P < 0.0001). Therefore, reduced 99mTc-cAbVCAM1-5 uptake in atorvastatin-treated mice was successfully monitored noninvasively by SPECT/CT imaging (0.87 ± 0.06 vs. 1.11 ± 0.09 percentage injected dose per cubic centimeter in control group, P < 0.05). Conclusion: 99mTc-cAbVCAM1-5 imaging allowed the specific, sensitive, and reproducible quantification of VCAM-1 expression in mouse atherosclerotic lesions. 99mTc-cAbVCAM1-5 therefore exhibits suitable characteristics for the evaluation of novel antiatherogenic agents.

[1]  Z. Fayad,et al.  Imaging Atherosclerosis and Vulnerable Plaque , 2010, Journal of Nuclear Medicine.

[2]  Marleen Keyaerts,et al.  Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer , 2013, The Journal of Nuclear Medicine.

[3]  Han Liu,et al.  Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis , 2009, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[4]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[5]  V. Fuster,et al.  Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin. , 2012, JACC. Cardiovascular imaging.

[6]  B. Kaufmann,et al.  Noninvasive Ultrasound Molecular Imaging of the Effect of Statins on Endothelial Inflammatory Phenotype in Early Atherosclerosis , 2013, PloS one.

[7]  V. Fuster,et al.  The year in atherothrombosis. , 2004, Journal of the American College of Cardiology.

[8]  M. Davies,et al.  The expression of the adhesion molecules ICAM‐1, VCAM‐1, PECAM, and E‐selectin in human atherosclerosis , 1993, The Journal of pathology.

[9]  S. Micuda,et al.  Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. , 2008, Life sciences.

[10]  Jakub Toczek,et al.  Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions , 2012, Circulation research.

[11]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[12]  C. Alpers,et al.  Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. , 1996, Circulation.

[13]  M. Farkouh,et al.  Emerging anti-inflammatory drugs for atherosclerosis , 2013, Expert opinion on emerging drugs.

[14]  Ralph Weissleder,et al.  18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. , 2009, JACC. Cardiovascular imaging.

[15]  Ralph Weissleder,et al.  The Vascular Biology of Atherosclerosis and Imaging Targets , 2010, Journal of Nuclear Medicine.

[16]  P. Barter,et al.  Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk , 2012, Journal of Lipid Research.

[17]  R. Ross,et al.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[18]  V. Fuster,et al.  Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. , 2011, JACC. Cardiovascular imaging.

[19]  P. Libby,et al.  Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.

[20]  M. Ferguson,et al.  Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. , 1993, The Journal of clinical investigation.

[21]  Ralph Weissleder,et al.  Noninvasive Vascular Cell Adhesion Molecule-1 Imaging Identifies Inflammatory Activation of Cells in Atherosclerosis , 2006, Circulation.

[22]  H. Drexler,et al.  Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. , 2005, Atherosclerosis.

[23]  Zahi A Fayad,et al.  Atherothrombosis and high-risk plaque: part I: evolving concepts. , 2005, Journal of the American College of Cardiology.

[24]  J. Jukema,et al.  Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels. , 2011, Atherosclerosis.

[25]  C. Ballantyne,et al.  Pharmacological strategies for lowering LDL cholesterol: statins and beyond , 2011, Nature Reviews Cardiology.

[26]  Z. Fayad,et al.  Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. , 2013, Journal of the American College of Cardiology.

[27]  P. Libby,et al.  Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. , 2013, American heart journal.

[28]  M. Abrar,et al.  Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake , 2011, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[29]  J. H. Rudd,et al.  Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. , 2012, JACC. Cardiovascular imaging.

[30]  Takashi Kato,et al.  Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  V. Fuster,et al.  The year in atherothrombosis. , 2013, Journal of the American College of Cardiology.

[32]  Antonio Colombo,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. , 2003, Circulation.

[33]  P. Hansen,et al.  Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. , 2001, The Biochemical journal.